Immunotoxin treatment of brain tumors.
Hall
W A
WA
Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
D000818:Animals; D001427:Bacterial Toxins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004167:Diphtheria Toxin / Q000009:adverse effects / Q000627:therapeutic use; D004337:Drug Carriers / Q000493:pharmacokinetics; D004357:Drug Synergism; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006168:Guinea Pigs; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015552:Injections, Intralesional; D007278:Injections, Spinal; D008024:Ligands; D008527:Medulloblastoma / Q000188:drug therapy* / Q000473:pathology; D008577:Meningeal Neoplasms / Q000188:drug therapy / Q000556:secondary; D051379:Mice; D008985:Monensin / Q000494:pharmacology; D010940:Plant Proteins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D011923:Rats, Nude; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014018:Tissue Distribution; D014168:Transferrin / Q000008:administration & dosage; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D001427:Bacterial Toxins; C058384:CRM 107; D004167:Diphtheria Toxin; D004337:Drug Carriers; D000922:Immunotoxins; D008024:Ligands; D010940:Plant Proteins; D011993:Recombinant Fusion Proteins; D014168:Transferrin; D008985:Monensin